|[May 20, 2014]
Aduro Announces Pancreatic Cancer and Mesothelioma Abstracts to Be Presented at 2014 ASCO Annual Meeting
BERKELEY, Calif. --(Business Wire)--
Aduro BioTech, Inc., a clinical stage biotechnology company, today
announced that two posters highlighting clinical trials of the company's
pancreatic cancer and mesothelioma immunotherapies will be presented at
the upcoming American Society of Clinical Oncology (ASCO) to be held in
The presentation will be at the following poster sessions:
Saturday, May 31, 8:00-11:45 a.m.
Abstract #: TPS4159
Title: A Phase 2B Randomized, Controlled, multicenter, Open-label
Study of the Efficacy and Immune Response of GVAX Pancreas Vaccine and
CRS-207 Compared to Chemotherapy or to CRS-207 alone in Adults with
Previously Treated Metastatic Pancreatic Adenocarcinoma (ECLIPSE Study)
Presenter: Dung Le, M.D., Assistant Professor of Oncology at the Johns
Hopkins Sidney Kimmel Comprehensive Cancer Center
Session: Gastrointestinal (Noncolorectal) Cancer
Location: S Hall A2
Sunday, June 1, 8:00-11:00 a.m.
Abstract #: 7532
Title: Antimesothelin Vaccine CRS-207 plus Chemotherapy as Front-line
Treatment for Malignant Pleural Mesothelioma (MPM)
Presenter: Raffitt Hassan, M.D., Head of the Solid Tumor Immunotherapy
Section at the Laboratory of Molecular Biology at the National
Session: Lung Cancer - Non-small Cell Local-regional/Small Cell/Other
About LADD and CRS-207
LADD is Aduro's proprietary platform of live-attenuated double-deleted listeria
monocytogenes strains that have been engineered to induce a potent
innate immune response and to express tumor-associated antigens to
induce tumor-specific T cell-mediated immunity. CRS-207 is engineered to
express mesothelin, which is expressed in pancreatic cancer,
mesothelioma and other cancers.
About GVAX and GVAX Pancreas
GVAX Pancreas is one of a family of GVAX vaccines derived human cancer
cell lines which are modified to secrete granulocyte-macrophage
colony-stimulating factor (GM-CSF), an immune-stimulatory cytokine.
Aduro's GVAX portfolio includes vaccines for pancreatic, prostate, colon
and breast cancers as well as multiple myeloma.
About Aduro BioTech, Inc.
Aduro BioTech, Inc. is a private, clinical-stage biotechnology company
focused on immunotherapy for cancer. Aduro has ongoing clinical trials
with its LADD platform in pancreatic cancer, mesothelioma and
glioblastoma and development programs in non-small cell lung cancer,
ovarian cancer and prostate cancer. The company is also developing
clinical candidates using novel small molecules that activate the
intracellular STING receptor, a central mediator of the innate immune
response. For more information, please visit www.adurobiotech.
[ Back To TMCnet.com's Homepage ]